| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ProQR Therapeutics N.V.$1.73
-0.03 (-1.7%)
D 33Pipeline Score Richly Valued Pharma · Clinical
Market Cap
164.36 M
EPS
-0.50
P/E Ratio
-
Value Trade
972.60 K
-3.7 %
Week
-11.86 %
1 Month
9.09 %
3 Month
-24.64 %
6 Month
-75.66 %
5 Year
-92.16 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
549.39 K
52 Week Range
1.33 - 3.10
% held by Insiders
32.35 %
% held by Institutions
26.99 %
Enterprise Value
86.70 M
Total Shares
105.35 M
Short %
1.12 %
Float Shares
86.81 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ProQR Therapeutics N.V.
813Total events
13Upcoming
147Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 13
Event history 800
Jun 26, 2026
Jun 25, 2026
Jun 25, 2026
▲Topline ReadoutAX-0810Clinical Data
Positive Phase 1 target engagement data for AX-0810 in healthy volunteers
cholestatic liver diseasessource ↗
Jun 2, 2026
Jun 2026
May 2026
◆Poster PresentationPresentation
RNA Society Annual Meeting poster on Axiomer platform advancements
May 15, 2026
◆Oral PresentationPresentation
ASGCT 29th Annual Meeting oral presentation on AX-2911 in MASLD/MASH
May 14, 2026
◆Oral PresentationPresentation
ASGCT 29th Annual Meeting oral presentation on AX-2402 in Rett syndrome
Drug Pipeline Intelligence
D33
Pipeline Score $16M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 42%
Micro Cap (rank 529 of 911)
Percentile RankProQR Therapeutics N.V. faces pipeline headwinds (33/100), with $448M risk-adjusted pipeline value, led by QR-421a in Retinitis Pigmentosa (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QR-421a Small molecule | Retinitis Pigmentosa | Phase 1 | NCT03780257 | 15% | $335M | COMPLETED | 20 | - | - | Oct 14, 2021 | - | Apr 20, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AX-0810 | biliary atresia | Phase 1 | 2026-06-25 | up to 8-fold change (6 mg/kg) in total bile acids in serum; exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation Read More | ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform Read More | |
AX-0810 | biliary atresia | Phase 1 | 2026-06-25 | up to 8-fold change (6 mg/kg) in total bile acids in serum; exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation Read More | ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform Read More | |
AX-0810 | biliary atresia | Phase 1 | 2026-06-25 | up to 8-fold change (6 mg/kg) in total bile acids in serum; exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation Read More | ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRQR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRQR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRQR▼ -13.5%on this news
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
ProQR Therapeutics has announced a successful pricing of a $50 million underwritten registered direct offering of ordinary shares at $1.81 each. Concurrently, Eli Lilly will purchase additional shares to maintain its ownership stake, contributing approximately $9.2 million. The proceeds will primarily support research and clinical development of ProQR's RNA therapies. The offering is expected to close on June 26, 2026.
Read more →PRQR▼ -13.5%on this newsshared move
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
ProQR Therapeutics announced positive Phase 1 data for AX-0810, showing significant target engagement in healthy volunteers. The study demonstrated dose-dependent increases in total bile acids, exceeding the predefined threshold for NTCP modulation. AX-0810 exhibited a favorable safety profile with no serious adverse events reported. The findings support further development of AX-0811 for biliary atresia.
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position at
PROQR Therapeutics N.V. has reported its financial results for the first quarter of 2026, revealing a comprehensive loss of €13.2 million, which is an increase from a €10.5 million loss in the same period last year. The company’s revenue fell sharply to €2.0 million compared to €4.5 million in Q1 2025. Operating costs also rose, affecting the overall financial performance negatively. With equity declining from €49.4 million to €37.6 million since the previous quarter, concerns over financial stability are evident.
Read more →PRQRProQR Announces First Quarter 2026 Operating and Financial Results
ProQR Therapeutics reported its Q1 2026 results, highlighting progress in its RNA editing pipeline, including the upcoming target engagement data for AX-0810 in biliary atresia. The company is expanding its pipeline with AX-0811 and AX-0422, while maintaining a strong cash position of €81.1 million. ProQR is also enhancing its Axiomer platform through AI partnerships and has nominated a new board member.
Read more →PRQRProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
ProQR Therapeutics has announced several upcoming presentations at scientific conferences, showcasing advancements in its Axiomer RNA editing platform. The presentations will cover various applications, including treatments for Hurler syndrome and Rett syndrome. The company anticipates initial clinical data for its lead program, AX-0810, in healthy volunteers later this quarter.
Read more →PRQR▲ +5.8%on this news
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
ProQR Therapeutics has announced its Annual General Meeting (AGM) of Shareholders scheduled for June 2, 2026, in Amsterdam. The meeting will cover important company updates and provide shareholders with access to relevant documents via the company's website. ProQR continues to develop its Axiomer RNA editing technology, which aims to create new therapies for various diseases.
Read more →PRQRProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
ProQR Therapeutics has nominated Dr. Lykke Hinsch Gylvin to its Board of Directors. Dr. Gylvin, currently the Chief Medical Officer at Boehringer Ingelheim, brings extensive experience in drug development. Her nomination will be submitted for shareholder approval at the upcoming Annual General Meeting. If approved, she will serve as an independent non-executive director.
Read more →PRQR▲ +7.6%on this news
EXPANDING THE AXIOMER RNA EDITING OPPORTUNITY BEYOND AX-0810 Nasdaq: PRQR |
ProQR Therapeutics is expanding its Axiomer RNA editing platform, focusing on the development of AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) and AX-0422 for Hurler Syndrome. AX-2911 has shown promising preclinical results, including a significant reduction in liver fat. Furthermore, the company is planning to initiate clinical trials for both therapies, aiming for first-in-human trials in 2027. This expansion underscores ProQR's strategic focus on addressing critical unmet medical needs in various conditions.
Read more →PRQR▲ +7.6%on this news
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
ProQR Therapeutics highlighted significant updates on its RNA editing pipeline during a recent Investor and Analyst event. The company announced progress on its lead program AX-0810, which is due to report target engagement data soon, and introduced new programs AX-0811 and AX-0422 aimed at treating cholestatic diseases and Hurler syndrome, respectively. The event underscored the strength of ProQR's proprietary Axiomer platform and projected multiple upcoming clinical data readouts, indicating a robust path forward in their development strategy.
Read more →PRQR▲ +7.6%on this news
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
ProQR Therapeutics has announced a partnership with Ginkgo Bioworks to enhance its AI-enabled drug discovery efforts using high-throughput data generation. Additionally, the company has formed an AI Advisory Board comprising industry experts to guide its AI strategy. ProQR expects to advance its first AI-discovered Development Candidate into clinical trials by 2026.
Read more →PRQR▲ +6%on this news
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
ProQR Therapeutics will host a virtual Investor and Analyst Event on April 8, 2026, to discuss its RNA editing pipeline, including the anticipated data for AX-0810. The event will feature presentations and a Q&A session, highlighting new clinical programs and the primary indication for AX-0810. ProQR aims to showcase its transformative RNA therapies and the potential of its Axiomer technology.
Read more →PRQRProQR Announces Year End 2025 Operating and Financial Results
ProQR Therapeutics reported its 2025 financial results, highlighting significant progress in its clinical pipeline, including the advancement of AX-0810 into Phase 1 trials. The company achieved collaboration milestones with Eli Lilly and selected new development candidates for Rett syndrome and MASH. However, it also reported an increase in net loss and a decrease in cash reserves compared to the previous year.
Read more →PRQR▲ +13.3%on this news· ran to +26% by day 3
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
ProQR Therapeutics N.V. has announced that its management will present at the Citizens Life Sciences Conference on March 11, 2026. The presentation will highlight the company's innovative Axiomer™ RNA editing technology, which aims to develop new treatments for diseases by making precise edits to RNA. A live webcast of the presentation will be available on ProQR's website.
Read more →PRQRProQR Announces Planned Changes to Board Composition
ProQR Therapeutics announced planned changes to its Board composition, with co-founder Dinko Valerio and Alison Lawton rotating off at the upcoming AGM. This decision reflects the company's growth and commitment to corporate governance. An executive search firm has been engaged to identify new candidates for the Board to enhance long-term value creation.
Read more →PRQRProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with
ProQR Therapeutics has announced positive initial data from its Phase 1 trial of AX-0810, indicating no safety concerns after four weeks of dosing. The company also provided updates on selected development candidates for AX-2402 and AX-2911, targeting Rett syndrome and metabolic liver disease, respectively. Additionally, ProQR highlighted a successful collaboration with Eli Lilly, which achieved significant financial milestones in 2025. Looking ahead to 2026, ProQR aims to advance its pipeline and provide further target engagement data for AX-0810.
Read more →PRQR▼ -9.4%on this news
ProQR to Participate in 8th Annual Evercore Healthcare Conference
ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference on December 4, 2025. The company is focused on its Axiomer RNA editing technology, which aims to create new medicines for diverse diseases. Webcast details will be available on ProQR's website, and archived webcasts will be accessible for 30 days post-event.
Read more →PRQR▼ -7.1%on this news
ProQR Announces Third Quarter 2025 Operating and Financial Results
ProQR Therapeutics reported its Q3 2025 results, highlighting a significant milestone with the CTA authorization for AX-0810, initiating its first-in-human study. The company has a strong cash position of approximately €106.9 million, allowing continued advancement of its RNA editing platform. However, the net loss has increased compared to the previous year, raising concerns about financial sustainability.
Read more →PRQR▼ -5.8%on this news· ran to -20% by day 3shared move
ENTERING THE CLINIC WITH AX-0810
ProQR Therapeutics has gained Clinical Trial Application (CTA) approval for AX-0810, initiating progression to first-in-human clinical trials targeting neurological applications of RNA editing. Safety, tolerability, pharmacokinetics, and biomarker-based target engagement data from the trial are anticipated by early 2026. The company's strong financial position and strategic partnerships bolster its capabilities in advancing this promising therapy for diseases with high unmet needs.
Read more →PRQR▲ +9.7%on this news
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
ProQR Therapeutics has received authorization for a Clinical Trial Application (CTA) for AX-0810, its lead investigational RNA editing oligonucleotide targeting cholestatic diseases. The Phase 1 study will assess safety and pharmacokinetics in healthy volunteers. Additionally, ProQR will host a virtual investor event on November 3, 2025, to discuss the study's details.
Read more →PRQRProQR to Participate in Upcoming Investor Conferences in October 2025
ProQR Therapeutics N.V. will participate in several investor conferences in October 2025. The company focuses on transformative RNA therapies using its proprietary Axiomer technology, which enables precise RNA editing. This platform aims to address both rare and prevalent diseases. Additional details about the conferences will be available on their website.
Read more →PRQRProQR Announces Second Quarter 2025 Operating and Financial Results
ProQR Therapeutics reported its financial and operational results for Q2 2025, highlighting the submission of a Clinical Trial Application for its lead program AX-0810 targeting NTCP for cholestatic diseases. The company has strong cash reserves of €119.8 million, which should sustain operations into mid-2027. ProQR is also advancing AX-2402 for Rett Syndrome towards clinical candidate selection. Plans for a virtual Analyst and Investor Event are set to provide further updates on its pipeline and data expectations later this year.
Read more →PRQRProQR Announces Upcoming Presentation at RNA Editing Summit
ProQR Therapeutics will present at the RNA Editing Summit from July 29-31, 2025, in Boston. The presentation will highlight preclinical data on its Axiomer RNA editing technology, particularly in CNS applications and its Rett program targeting MECP2. This follows the submission of a Clinical Trial Application for AX-0810 aimed at cholestatic diseases.
Read more →PRQR▼ -5.6%on this news
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
ProQR Therapeutics has submitted a Clinical Trial Application to the EMA for AX-0810, a Phase 1 study targeting NTCP to address cholestatic liver diseases. This investigational therapy aims to reduce toxic bile acid accumulation in the liver. The study is expected to begin in the Netherlands, with initial data anticipated in Q4 2025.
Read more →PRQRProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
ProQR Therapeutics has announced its participation in two upcoming scientific conferences: the ASGCT 28th Annual Meeting and the TIDES USA 2025 Conference. The presentations will showcase their Axiomer RNA editing technology, which is designed to provide transformative benefits for patients. The company aims to highlight its innovative pipeline and the potential of its RNA therapies.
Read more →PRQRProQR Announces First Quarter 2025 Operating and Financial Results
ProQR Therapeutics reported its financial and operational results for Q1 2025, highlighting a cash position of €132.4 million, providing a financial runway until mid-2027. The company is on track to file a Clinical Trial Application for its lead program AX-0810 in Q2 2025, targeting cholestatic diseases. Recent appointments of new financial and medical leadership aim to support its growth and R&D initiatives. However, the company also recorded an increased net loss and operational cash usage compared to the previous year.
Read more →PRQR▲ +15.7%on this news
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
ProQR Therapeutics announced its participation in the 2025 Citizens Life Sciences Conference, scheduled for May 8. The company will present its innovative Axiomer RNA editing technology, which aims to develop new therapies for various diseases. A live webcast of the presentation will be available, along with a replay for 30 days.
Read more →PRQRProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
ProQR Therapeutics N.V. has announced that its Annual General Meeting (AGM) of Shareholders will be held on June 3, 2025, in Amsterdam. The meeting will provide shareholders with access to relevant documents and information through the company's website. ProQR is recognized for its pioneering Axiomer RNA editing technology aimed at developing new medicines for various diseases.
Read more →PRQR▲ +5.4%on this news
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth LEIDEN, Netherlands &
ProQR Therapeutics announced the appointment of Dennis Hom as CFO and Dr. Cristina Lopez Lopez as CMO, focusing on advancing its Axiomer RNA editing technology. These appointments are intended to support ProQR as it progresses its pipeline into clinical development. Both individuals bring significant experience in finance and translational medicine, which ProQR aims to leverage for its strategic goals. Current executives will transition out but remain through this period to ensure continuity.
Read more →PRQR▼ -5.9%on this news
ProQR Announces Year End 2024 Operating and Financial Results Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NT
ProQR Therapeutics NV reported its 2024 financial and operating results, highlighting advancements in its Axiomer ADAR-mediated RNA editing pipeline. The company is preparing for clinical data readouts in 2025 and 2026, with a CTA filing for its lead program, AX-0810, anticipated in Q2 2025. Despite a net loss of $27.8 million for the year, ProQR's strategic partnerships and strong cash position are expected to support its growth in RNA therapies. The company aims to leverage its innovative platform to address unmet medical needs.
Read more →PRQRINVESTOR &
ProQR Therapeutics is advancing its clinical pipeline with multiple candidates expected to produce trial data in 2025-2026, including treatments for cholestatic diseases and Rett syndrome. The company's collaboration with Eli Lilly presents opportunities for significant milestone revenues, further supported by a strong cash position. While the company is well-positioned for growth, uncertainties around clinical trials and therapy effectiveness remain. ProQR plans continued investments in expanding its intellectual property and discovery pipeline.
Read more →PRQRProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration LEIDEN, Netherlands &
ProQR Therapeutics has announced an expansion of its collaboration with the Rett Syndrome Research Trust, securing an additional $8.1 million in funding. This funding is aimed at advancing AX-2402 into clinical trials for treating Rett Syndrome, a rare neurodevelopmental disorder. The collaboration underscores ProQR's commitment to addressing unmet medical needs and advancing its proprietary Axiomer RNA editing technology. With a total of $9.1 million in funding, ProQR is optimistic about the progress of its RNA editing therapeutic candidates targeting MECP2 mutations.
Read more →PRQRProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist LEIDEN, Netherlands &
ProQR Therapeutics has appointed Dr. Peter A. Beal as Chief ADAR Scientist, aiming to strengthen its RNA editing platform. Dr. Beal, a prominent expert in ADAR and RNA biology, will enhance the development of the company’s Axiomer platform. He has previously contributed to ProQR's Scientific Advisory Board and has a notable research background at UC Davis. His role is expected to bolster ProQR's efforts in delivering therapeutic solutions for genetic diseases.
Read more →PRQRProQR Therapeutics to Host Virtual Analyst and Investor Event on
ProQR Therapeutics has announced it will host a virtual Analyst and Investor Event on December 11, 2024, highlighting its innovative Axiomer ADAR-mediated RNA editing platform. The event will include a Q&A session with key members of the management team and provide updates on various pipeline candidates. This initiative reflects ProQR's focus on transparency and engagement with stakeholders as it advances its therapeutic programs.
Read more →PRQRProQR Announces Third Quarter 2024 Operating and Financial Results
ProQR Therapeutics reported its third quarter 2024 financial results, highlighting a net loss increase to €8.1 million and reduced cash reserves. The company successfully raised $82.1 million from an equity financing, enhancing its financial stability until mid-2027. Notably, the AX-0810 program targeting cholestatic diseases is set to enter clinical trials, with an upcoming Investor and Analyst Event scheduled for December to discuss further developments and pipeline advancements.
Read more →PRQRProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
ProQR Therapeutics N.V. has announced the closure of an underwritten public offering of 18 million ordinary shares, raising $63 million. Additionally, the company completed a private placement of 3.52 million shares with Eli Lilly, generating approximately $12.3 million. These transactions aim to bolster ProQR's financial position to support the development of their innovative RNA therapies using the Axiomer technology platform. The company continues to focus on creating medicines for diseases with unmet medical needs.
Read more →PRQR▼ -7.7%on this newsshared move
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
ProQR Therapeutics announced a public offering of 18 million shares at $3.50 per share, raising approximately $63 million. Concurrently, ProQR will engage in a private placement with Eli Lilly, ensuring Lilly maintains its 16.4% ownership. The funds from the offering and placement are aimed primarily at supporting research and clinical development of ProQR's RNA therapies. The offering is expected to close on October 24, 2024, pending customary conditions.
Read more →PRQR▼ -6.7%on this newsshared move
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands &
ProQR Therapeutics N.V. has announced the commencement of an underwritten public offering of its ordinary shares, with all shares offered by ProQR. The net proceeds are intended to fund research and development, as well as support for clinical advancement of its product candidates. The offering is subject to market conditions, and the company has outlined potential risks associated with its forward-looking statements and the ability to complete the offering.
Read more →PRQRProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
ProQR Therapeutics announced that it will present preclinical data for its Axiomer™ RNA editing technology at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal from October 6-9, 2024. Co-founder Gerard Platenburg is scheduled to speak on October 8 about using oligonucleotide-guided RNA editing for cholestatic diseases. The Axiomer technology aims to modify RNA and potentially correct disease-causing mutations, positioning ProQR as a pioneering force in RNA therapeutics. Following the presentation, the slide deck will be accessible on the company's website.
Read more →PRQRProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
ProQR Therapeutics announced its participation in the 2024 Cantor Global Healthcare Conference, which will be held in New York City on September 17, 2024. The event will feature a webcast of the company's presentation, providing insights into its innovative RNA editing technology, Axiomer™, which targets specific mutations to develop new therapies. ProQR is focused on creating transformative RNA therapies for both rare and widespread diseases, using its proprietary editing platform. The company emphasizes its commitment to addressing unmet medical needs through its unique approach.
Read more →PRQR▲ +12.3%on this news
ProQR Announces Second Quarter 2024 Operating and Financial Results
ProQR Therapeutics has announced its second quarter 2024 financial results, reporting advancements in its clinical programs AX-0810 and AX-1412. The company achieved significant milestones in its partnership with Eli Lilly, contributing to a robust cash position of €96.2 million. ProQR also plans to provide more translational data and trial designs for its upcoming therapies in late 2024 and early 2025. However, the company continues to report net losses and rising R&D costs, underscoring ongoing financial challenges.
Read more →PRQRProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Therapeutics will present on its Axiomer™ RNA editing technology at the RNA Editing Summit in Boston, scheduled for June 18-20, 2024. Gerard Platenburg, ProQR's Chief Scientific Officer, will discuss the development and optimization of this innovative technology and its applications in treating cholestatic diseases. The Axiomer platform leverages the body's own ADAR machinery for targeted RNA modifications, offering potential new therapies for various diseases. The presentation will be accessible on ProQR's website following the event.
Read more →PRQRProQR Announces First Quarter 2024 Operating and Financial Results
ProQR Therapeutics announced its first quarter 2024 financial and operational results, highlighting significant advancements in its AX-0810 program targeting NTCP for cholestatic diseases. Key presentations at the ASGCT Annual Meeting included compelling preclinical data demonstrating RNA editing capabilities. The company reported a cash reserve of €102.7 million, ensuring operational runway into mid-2026, alongside plans for multiple clinical milestones in the near future. Furthermore, ProQR affirmed its strong intellectual property position with successful patent defenses.
Read more →PRQRProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR Therapeutics has announced promising preclinical proof of concept data for its AX-0810 Axiomer RNA editing program, which targets NTCP to address cholestatic diseases. This represents a significant milestone in RNA editing, showing meaningful changes in serum biomarkers during studies conducted on non-human primates. The findings were presented at the ASGCT Annual Meeting, highlighting the potential therapeutic impact of ProQR’s innovative Axiomer technology. The company is gearing up to enter clinical trials for AX-0810 by late 2024 or early 2025, with further details expected to be shared soon.
Read more →PRQRProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held
ProQR Therapeutics has announced the nomination of Dr. Martin Maier to its Board of Directors and scheduled its Annual General Meeting for May 22, 2024. Dr. Maier brings extensive experience in RNA platforms from his role at Alnylam Pharmaceuticals. The company is transitioning to a one-tier board structure to align with common practices in the biotech industry. ProQR's Axiomer technology platform, which aims to revolutionize RNA therapies, continues to be developed as new therapeutic programs approach clinical trials.
Read more →PRQRProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
ProQR Therapeutics announced it will present new preclinical data for its Axiomer RNA editing technology at the ASGCT Annual Meeting. The data includes initial proof of concept for the AX-0810 program targeting cholestatic diseases, highlighting the potential of the Axiomer platform. With robust editing efficiency, the company aims to advance this promising technology towards clinical applications. However, the company acknowledges risks and uncertainties that could affect timelines and results during development.
Read more →PRQR▲ +7%on this newsshared move
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio LEIDEN, Netherlands &
ProQR Therapeutics has successfully defended its Axiomer patent against a challenge from a strawman at the European Patent Office. The Opposition Division ruled that ProQR's intellectual property related to chemically modified RNA editing oligonucleotides remains strong. This decision reinforces ProQR's position in the RNA editing space and highlights the value of its proprietary platform technology. ProQR continues to invest in its patent estate, aiming to develop therapeutic options for various diseases based on the Axiomer technology.
Read more →PRQR▲ +13.7%on this news
ProQR Announces Year End 2023 Operating and Financial Results Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GAL
ProQR Therapeutics has announced its financial and operating results for the year ending December 31, 2023, highlighting advancements in its RNA editing technology platform, Axiomer. The company revealed its initial pipeline programs, AX-0810 and AX-1412, targeting cholestatic diseases and cardiovascular disorders, respectively. With a strong cash position and strategic partnerships, ProQR aims to begin clinical trials for these programs in late 2024 or early 2025. Notably, the company reported a positive cash flow for 2023, contrasting with a net loss compared to the previous year, reflecting ongoing challenges amidst its transitions.
Read more →PRQRProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands &
ProQR Therapeutics announced that it successfully defended its Axiomer patent against opposition in Japan, with the Japanese Patent Officemaintaining all claims as granted. This patent is central to ProQR's ADAR-mediated RNA editing platform, which utilizes chemically modified oligonucleotides to target specific RNA through endogenous enzymes. The ruling reaffirms the strength of ProQR's intellectual property in RNA editing, which has been upheld in multiple jurisdictions. ProQR's commitment to maintaining and expanding its patent estate is aimed at supporting its long-term success in developing RNA therapies for various diseases.
Read more →PRQRProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024 Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-hu
ProQR Therapeutics NV presented new data from its Axiomer RNA editing technology platform during the Deaminet 2024 conference. The highlighted results demonstrated effective in vivo editing, achieving up to 70% editing of the ACTB gene in the liver of non-human primates. The company's Chief Scientific Officer emphasized the exciting potential of Axiomer EONs for addressing various liver and CNS disorders. ProQR is looking forward to advancing its technology towards human clinical trials.
Read more →PRQRProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration Partnership focused on utilizing Axiomer to develop editing oligonucleotides targeting an underlying genetic variant that causes R
ProQR Therapeutics has announced a collaboration with the Rett Syndrome Research Trust to develop RNA editing oligonucleotides targeting genetic mutations related to Rett syndrome. This collaboration aims to expand ProQR's commitment to therapies for central nervous system diseases. Initially funded by a $1 million grant, the project will focus on utilizing ProQR's Axiomer technology to develop editing oligonucleotides that correct mutations in the MECP2 gene. This partnership represents a significant step forward in advancing the treatment landscape for this rare neurodevelopmental disorder.
Read more →PRQRProQR Therapeutics Announces Transaction Completed for Th a to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Divestment of sepofarsen and ultevursen completed - Th a to continue development of sepofarsen and ultevu
ProQR Therapeutics has completed the divestment of its late-stage ophthalmic assets, sepofarsen and ultevursen, to Laboratoires Th a. This transaction provides ProQR with an initial payment of 8 million USD, with the potential for up to 165 million USD in additional earn-out payments based on milestones. Th a will continue to develop these therapies for patients with LCA10 and Usher Syndrome, while ProQR focuses on advancing its Axiomer RNA editing platform for other diseases. The transaction reflects ProQR's strategic realignment of its development efforts.
Read more →PRQR▲ +10.7%on this news
ProQR Announces Third Quarter 2023 Operating and Financial Results
ProQR Therapeutics announced its third-quarter results for 2023, highlighting advancements in its Axiomer® RNA editing platform and pipeline programs targeting cholestatic diseases and cardiovascular conditions. The company reported holding €120.6 million in cash, extending its financial runway to mid-2026. ProQR successfully defended its intellectual property rights in Japan while enhancing its IP position with a new patent in the US, which underscores its proprietary RNA editing technology. Looking ahead, ProQR plans to release additional preclinical data and continue collaboration with Eli Lilly.
Read more →PRQRProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
ProQR Therapeutics has announced the issuance of a new patent from the USPTO, which expands protections related to its RNA editing technology using endogenous ADAR. In addition, the company successfully defended its patent rights against an opposition challenge in Japan. These developments solidify ProQR's leading position in intellectual property associated with its Axiomer RNA editing platform, which could provide a new class of medicines targeting various diseases. The company continues to innovate and expand its patent estate, emphasizing the importance of safeguarding its intellectual assets for long-term success.
Read more →PRQRProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
ProQR Therapeutics NV has announced that its CEO, Daniel A. de Boer, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic Medicines Conference in New York City on October 2, 2023. The event will also include 1x1 meetings with investors, promoting engagement with the investment community. ProQR is advancing its proprietary Axiomer RNA editing technology, aimed at creating targeted edits in RNA to treat various diseases. Recordings of the conference session will be made available afterward on the company's website.
Read more →PRQRProQR Therapeutics Provides Update on Ophthalmic Assets LEIDEN, Netherlands &
ProQR Therapeutics announced that its agreement to divest its late-stage ophthalmic assets to Laboratoires Th a has been terminated due to key personnel opting not to join Th a. CEO Daniel A. de Boer expressed disappointment over the termination but reaffirmed ProQR's focus on their Axiomer RNA editing platform. The company aims to advance its pipeline, especially for cholestatic and cardiovascular diseases, while continuing its partnership with Eli Lilly.
Read more →PRQRProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
ProQR Therapeutics NV (Nasdaq: PRQR) has announced its participation in the HC Wainwright 25th Annual Global Investment Conference, with a webcast presentation scheduled for September 11, 2023. This event will highlight the company's pioneering work in RNA therapies through its Axiomer® RNA editing technology platform. The archived webcast will be available for approximately 30 days, offering investors extended access to the information shared. ProQR's commitment to transformative RNA therapies focuses on addressing various diseases using its innovative technology.
Read more →PRQRProQR Announces Second Quarter 2023 Operating and Financial Results
ProQR Therapeutics announced its financial and operational results for the second quarter of 2023, highlighting a cash balance of €129 million, which supports its runway into mid-2026. The company is divesting its late-stage ophthalmic programs to Théa, allowing it to concentrate on its Axiomer RNA editing platform. Future updates on preclinical data and progress for its pipeline programs, especially for cholestatic diseases and cardiovascular risk, are anticipated in the upcoming quarters. This strategic focus could position ProQR favorably within the RNA therapy landscape.
Read more →PRQR▲ +7.3%on this newsshared move
ProQR Therapeutics and Laboratoires Th a Announce Agreement for Th a to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets Agreement provides ProQR with initial payment of 12.5M and up to 135M in further payment
ProQR Therapeutics has entered into an agreement with Laboratoires Th a for the acquisition of its ophthalmic assets, sepofarsen and ultevursen. The deal includes an initial payment of $12.5 million, with the potential for up to $135 million in additional payments based on commercial sales in the US and EU. This divestment enables ProQR to refocus its resources on advancing its Axiomer RNA editing platform and ongoing pipeline programs aimed at genetic diseases affecting the liver. The transaction is expected to close in the third quarter of 2023, pending certain conditions.
Read more →PRQRProQR to Present Data on its Axiomer RNA Editing Technology at RNA Editing Summit
ProQR Therapeutics will present its Axiomer RNA editing technology at the RNA Editing Summit from July 11-13, 2023, in Boston, MA. The presentation aims to discuss strategies to enhance RNA editing yields and the potential applications of the Axiomer platform for treating liver-originated disorders, supported by data from preclinical models. ProQR's advancements may lead to new therapies for a range of diseases. However, the company acknowledges various risks associated with clinical trials and collaborations in its forward-looking statements.
Read more →PRQR▼ -7.3%on this news
ProQR Announces First Quarter 2023 Operating and Financial Results
ProQR Therapeutics NV reported its first-quarter 2023 operating and financial results, highlighting the development of its Axiomer RNA editing technology platform. The company aims to advance two initial pipeline programs targeting Cholestatic Diseases and Cardiovascular Disease, with expectations of moving these into clinical development by late 2024 or early 2025. ProQR's financial position remains robust with €139 million in cash, while it successfully defended a critical patent, reinforcing its intellectual property stance. Upcoming events and presentations are planned over the next year to showcase further advancements and data.
Read more →PRQRProQR to Present its Axiomer RNA Editing Technology at TIDES USA 2023
ProQR Therapeutics announced its participation in TIDES USA 2023 where it presented data on its Axiomer RNA editing technology. The presentation, led by Co-Founder Gerard Platenburg, focused on innovative Editing Oligonucleotides (EONs) that may address liver-originated disorders. Results look promising, revealing significant editing efficiency improvements in animal models. However, the company also highlighted possible risks associated with the technology's development and regulatory processes.
Read more →PRQRProQR Announces Upcoming Investor Conferences in April and May
ProQR Therapeutics NV has announced its participation in several upcoming investor conferences, including the Van Lanschot Kempen Life Sciences Conference and the JMP Securities Life Sciences Conference. The company intends to showcase its Axiomer® RNA editing technology, which promises new treatments for various diseases. ProQR is focused on advancing its proprietary RNA therapies and will provide webcast details for investors. However, the company also highlights potential uncertainties related to clinical trial timelines and regulatory processes.
Read more →PRQR▼ -6.5%on this newsshared move
ProQR Announces Annual Meeting of Shareholders to be Held
ProQR Therapeutics NV announced that its Annual General Meeting (AGM) will take place on May 17, 2023, in Amsterdam, Netherlands. The meeting will cover various important topics, including company updates and shareholder engagement. ProQR continues to pioneer RNA editing through its Axiomer platform, which holds promise for developing new therapies for a range of diseases. Shareholders can access meeting documents through the company's website, ensuring transparency and communication with stakeholders.
Read more →PRQR▼ -29.6%on this news· ran to -44% by day 1
ProQR Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology at R&D Event Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular
ProQR Therapeutics has announced initial pipeline programs utilizing its Axiomer RNA editing technology, targeting cholestatic diseases and cardiovascular conditions. The virtual R&D event highlighted their programs AX-0810 and AX-1412, and provided updates on the financial position and future milestones. The company also emphasized a strong partnership with Eli Lilly and plans to extend its pipeline into clinical trials. ProQR's cash reserves are projected to sustain operations through mid-2026, despite reporting a net loss for 2022.
Read more →PRQR▲ +7.8%on this news
ProQR Announces Successful Defense of a Key Axiomer Patent Protecting ADAR-mediated RNA Editing
ProQR Therapeutics announced a successful defense of its Axiomer patent related to ADAR-mediated RNA editing, ruling favorable after EPO hearings. The patent, critical for their RNA editing technology platform, faced two oppositions. ProQR's extensive IP estate, which includes multiple patents, supports its innovative approach to RNA therapies. The company remains optimistic about advancing its Axiomer technology to address unmet medical needs.
Read more →PRQRProQR to Present at Upcoming Scientific and Industry Conferences
ProQR Therapeutics N.V. announced several presentations at upcoming scientific and industry conferences in March 2023. The highlights include discussions on the company's proprietary Axiomer RNA editing technology platform, which utilizes Editing Oligonucleotides for RNA targeting and therapeutic potential. Key presentations will take place at the Oligonucleotide and Precision Therapeutics Congress, RNA Leaders Europe Congress, and RNA Editing Gordon Research Conference, featuring executives from ProQR. The company aims to address high unmet medical needs by advancing its RNA editing therapies.
Read more →PRQRProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
ProQR Therapeutics N.V. announced a virtual R&D event scheduled for March 29, 2023, where it will present its Axiomer® RNA-editing technology and discuss pipeline targets. The event will also feature a Q&A session with the ProQR management team, including insights from industry experts. Additionally, the company is set to reveal its financial results for the full year 2022 during the event. This development highlights ProQR's ongoing commitment to advancing RNA therapies.
Read more →PRQR▲ +63.6%on this news· ran to +85% by day 3
ProQR Announces Conference Call to Discuss Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and we
Read more →PRQR▲ +63.6%on this news· ran to +85% by day 3
Lilly and ProQR to Expand RNA Editing Collaboration New agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS; LEI
Lilly and ProQR to Expand RNA Editing supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR's Axiomer technology INDIANAPOLIS; LEIDEN, Netherlands; and CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) - Eli Lilly an
Read more →PRQR▲ +5.2%on this news· ran to +21% by day 3
ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and
Read more →PRQRProQR Announces Third Quarter 2022 Operating and Financial Results
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023 Management Team appointments and planned additions to the Su
Read more →PRQRProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies
Read more →PRQRProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer RNA editing te
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology & CAMBRIDGE, Mass., August 11, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies, toda
Read more →PRQRProQR Announces Second Quarter 2022 Operating and Financial Results
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an u
Read more →PRQRProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will participate i
Read more →PRQR▲ +12%on this news
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates Annual General Meeting of Shareholders to be held on
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates LEIDEN, Netherlands & CAMBRIDGE, Mass., June 1, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative R
Read more →PRQR▼ -9%on this news
ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and P
Read more →PRQRProQR Announces First Quarter 2022 Operating and Financial Results
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and provide an up
Read more →PRQR▼ -5.8%on this news
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th Annual R
Read more →PRQRProQR to Participate in the Kempen Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will participate
Read more →PRQR▼ -12.6%on this newsshared move
STRATEGY UPDATE Nasdaq: PRQR Date
PS, PN) Published 0026 11 Feb 2019 - EONs with UNA modifications - EONs with phosphonacetate linkages Published 0029 03 Apr 2019 EONs with methylphosponate linkages Published 0031 24 Apr 2019 Targeted editing inhibition Published 0032 13 Jun 2019 EONs with base modifications for
Read more →PRQR▼ -12.6%on this newsshared move
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing acti
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy Netherlands & CAMBRIDGE, Mass., April 13, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of trans
Read more →PRQR▲ +8.9%on this news
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a presentation a
Read more →PRQRProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company man
Read more →PRQRProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraga
Read more →PRQRProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and re
Read more →PRQR▼ -75.4%on this news
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290 -mediated LCA10 Study did not meet primary endpoint nor notable secondary endpoints - no benefit observed in either treatment arm v
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 Study did not meet primary endpoint nor notable secondary endpoints - no benefit observed in either treatment arm versus sham Additional analyses to be conducted and pres
Read more →PRQR▲ +9.6%on this news
ProQR to Present at Upcoming SVB Leerink Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company mana
Read more →PRQRProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
Top-line data now expected to be announced in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Thera
Read more →PRQRProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital LEIDEN, Netherlands &
Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital LEIDEN, Netherlands & CAMBRIDGE, Mass., December 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) ("ProQR"), a company dedicated to changing lives through the
Read more →PRQRProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A mediated Retinitis Pigmentosa LEIDEN, Netherlands &
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A mediated Retinitis Pigmentosa LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) - ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the
Read more →PRQRProQR Announces Highlights from Analyst Event
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Ev
Read more →PRQRProQR Announces Highlights from Analyst Event LEIDEN, Netherlands &
Announces Highlights from Analyst Event Netherlands & CAMBRIDGE, Mass., November 18, 2021 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hoste
Read more →PRQRProQR to Webcast Virtual Analyst Event on November 18
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Analyst Ev
Read more →PRQRProQR Announces Upcoming Investor Conferences in November and December
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company mana
Read more →PRQR▲ +5.6%on this newsshared move
ProQR Announces Third Quarter 2021 Operating and Financial Results
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022 Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing platform and strengthens financial position
Read more →PRQRProQR Appoints Theresa Heggie as Chief Commercial Officer Senior leader with extensive global rare disease commercialization experience Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-media
ProQR Appoints Theresa Heggie as Chief Commercial LEIDEN, Netherlands & CAMBRIDGE, Mass., October 4, 2021 - ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, toda
Read more →PRQRProQR Announces Conference Call to Discuss the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that ProQR management wi
Read more →PRQRProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lilly Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR's proprietary Axiomer RNA edit
ProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lilly LEIDEN, Netherlands & CAMBRIDGE, Mass., September 8, 2021 -ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and Comp
Read more →PRQRProQR Announces Virtual Presentation at EURETINA 2021
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of da
Read more →PRQRProQR Announces Upcoming Investor Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company man
Read more →PRQRProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company mana
Read more →PRQRProQR Announces Second Quarter 2021 Operating and Financial Results
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by year end 2021 Initial clinical data from Phase
Read more →PRQRProQR to Present at Upcoming JMP Securities Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company mana
Read more →PRQRProQR Announces First Quarter 2021 Operating and Financial Results
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to
Read more →PRQRProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target Yarrow Biotechnology, Inc., a newly formed bi
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lea
Read more →PRQRProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentati
Read more →PRQRProQR Announces Participation in Upcoming Kempen Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced tha
Read more →PRQRProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the
Read more →PRQRProQR Announces Annual Meeting of Shareholders LEIDEN, Netherlands &
ProQR Announces Annual Meeting of Shareholders LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal dis
Read more →PRQRProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the publication in the sc
Read more →PRQRProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the closing of it
Read more →PRQRProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at
Read more →PRQRProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands and
ProQR Prices $90 Million Underwritten Public Offering of Ordinary LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retina
Read more →PRQRProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to
Read more →PRQRQR-421A STELLAR Trial results
Please register to watch the full presentation. Results of Stellar Phase 1/2 Trial By Aniz Girach, MD, Chief Medical Officer QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) Potential first-in-class RNA therapy QR-421a targets Exon 13 mutations in Ush2a (
Read more →PRQRProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visua
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials LEIDEN, Netherlands & CAMBRIDGE, Mass., March 24, 2021 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through t
Read more →PRQRProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced tha
Read more →PRQRProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced tha
Read more →PRQRProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021 QR-421a Stellar Pha
Read more →PRQRProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that
Read more →PRQRProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Top-line results expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Top-line results expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Net
Read more →PRQRProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that
Read more →PRQRProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that
Read more →PRQRProQR Announces Third Quarter 2020 Operating and Financial Results
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021 Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim analysis expected in H1 2021
Read more →PRQRProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual poster presentatio
Read more →PRQRProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Ÿ Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally LEIDEN, Netherlands &
Appoints Naveed Shams, MD, PhD as Chief Scientific Officer LEIDEN, Netherlands & CAMBRIDGE, Mass., October 5, 2020 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited
Read more →PRQRProQR Announces Virtual Presentations at Scientific Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at
Read more →PRQRProQR to Participate in Upcoming Investor Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for inherited retinal diseases (IRDs), today announced tha
Read more →PRQRProQR Announces Second Quarter 2020 Operating and Financial Results
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial; Strategic convertible debt financing extends runway into 2023 if fully drawn; Trial enrollm
Read more →PRQRProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the C
Read more →PRQRForward looking statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as antici
EXPERT PERSPECTIVES CALL Sepofarsen InSight Open Label Extension Study Update July 20, 2020 Exhibit 99.1 Forward looking statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, whi
Read more →PRQRProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Extends ProQR s cash runway into 2023 ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Extends ProQR s cash runway into 2023 ProQR can trigger conversion of the debt to equity at $7.88 per share, under certain conditions LEIDEN, Netherlands & CAMBRIDGE, Mass., July
Read more →PRQRProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will host
Read more →PRQRProQR Announces Expert Perspectives Conference Call Series
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will laun
Read more →PRQRProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of
Read more →PRQRProQR Announces First Quarter 2020 Operating and Financial Results
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned; Updated data from the Phase 1/2 InSight extension study of sepofarsen, includ
Read more →PRQRProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update QR-421a showed early and encouraging evidence of activity, with 25% of patients
ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measu
Read more →PRQRProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management w
Read more →PRQRProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021 Phase 1/2 Stellar trial i
Read more →PRQRProQR to Present at Cowen and Company 40th Annual Health Care Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that Comp
Read more →PRQRProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker Program for People Living with Inherited Retinal Diseases
LEIDEN, Netherlands and CAMBRIDGE, Mass, Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced today its participation in the
Read more →PRQRProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene LEIDEN, Netherlands &
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) ProQR Therapeuti
Read more →PRQRProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands &
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the cr
Read more →PRQRFINAL FOR RELEASE ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands &
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of tra
Read more →PRQRProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan
Read more →PRQRProQR to Present at Upcoming Scientific Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Co
Read more →PRQRProQR to Present at Upcoming Investor Conferences
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that Co
Read more →PRQRProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 QR-1123 Investigational New Drug application active for autosomal dominant retinitis pigmentosa
Read more →PRQRProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares LEIDEN, the Netherlands and
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicin
Read more →PRQRProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pedi
Read more →PRQRProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Reported rapid, significant and durable improvements in vision at twelve months Concordant improvement in key secondary o
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Reported rapid, significant and durable improvements in vision at twelve months Concordant improvement in key secondary outcome measures The target registration dose of sepofarse
Read more →PRQRProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will p
Read more →PRQRProQR to Present at Two Investor Conferences in October
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that t
Read more →PRQRProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands &
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of tra
Read more →PRQRProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) LEIDEN, Netherlands &
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) LEIDEN, Netherlands & CAMBRIDGE, Mass., August 12, 2019 (GLOBE NEWSWIRE) ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing liv
Read more →PRQRProQR Announces Financial Results for the Second Quarter of 2019
LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its fina
Read more →PRQREuropean Medicines Agency Grants PRIME Access to ProQR s Sepofarsen for Leber s Congenital Amaurosis 10 Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation pro
European Medicines Agency Grants PRIME Access to ProQR s Sepofarsen for Leber s Congenital Amaurosis 10 Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with t
Read more →PRQRProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
LEIDEN, Netherlands and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced an upco
Read more →PRQRProQR to Present at the JMP Securities Life Sciences Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced tha
Read more →PRQRProQR to Present at the RBC Capital Markets Healthcare Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that
Read more →PRQRProQR Announces Financial Results for the First Quarter of 2019 LEIDEN, Netherlands &
ProQR Announces Financial Results for the First Quarter of 2019 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 8, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe gene
Read more →PRQRProQR to Present at Three Scientific Conferences in April
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcomi
Read more →PRQRProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filiu
Read more →PRQRProQR Announces Annual Meeting of Shareholders LEIDEN, Netherlands and
ProQR Announces Annual Meeting of Shareholders LEIDEN, Netherlands and CAMBRIDGE, Mass., April 18, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare dise
Read more →PRQRProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 LEIDEN, Netherlands &
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 LEIDEN, Netherlands & CAMBRIDGE, Mass., Apr. 15, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatme
Read more →PRQRProQR to Present at the H.C. Wainwright Global Life Sciences Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that m
Read more →PRQRProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership LEIDEN, Netherlands &
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., Mar. 26, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the
Read more →PRQRProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 LEIDEN, Netherlands &
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 LEIDEN, Netherlands & CAMBRIDGE, Mass., Mar. 11, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for t
Read more →PRQRProQR to Present at Cowen Health Care Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that t
Read more →PRQRProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results LEIDEN, Netherlands &
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatme
Read more →PRQRProQR Announces ProQR Vision 2023 Strategy at its Annual R&D Day LEIDEN, the Netherlands &
ProQR Announces ProQR Vision 2023 Strategy at its Annual R&D Day LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan 29, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its ProQR
Read more →PRQRProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it h
Read more →PRQRFINAL FOR RELEASE ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber s Congenital Amaurosis 10 LEIDEN, Netherlands &
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber s Congenital Amaurosis 10 LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan 07, 2019 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the cre
Read more →PRQRProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY. The R&D day will feature
Read more →PRQRProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it r
Read more →PRQRProQR Therapeutics Added to NASDAQ Biotechnology Index
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that as o
Read more →PRQRProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pub
Read more →PRQRFINAL FOR RELEASE ProQR Announces Strategic Changes to the Management Team and Key New Hires LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec 13 2018 ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company ), a company dedicated
ProQR Announces Strategic Changes to the Management Team and Key New Hires LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec 13 2018 ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company ), a company dedicated to changing lives through the creation of transformative RNA medicines for th
Read more →PRQRProQR Announces Strategic Changes to the Management Team and Key New Hires
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today an
Read more →PRQRProQR Receives 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 LEIDEN, Netherlands &
ProQR Receives 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec 10, 2018 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for t
Read more →PRQRProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients LEIDEN, Netherlands &
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA med
Read more →PRQRProQR to Present at the Evercore ISI HealthConX Conference
LEIDEN, the Netherlands, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the management will
Read more →PRQRProQR Announces Financial Results for the Third Quarter of 2018
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today
Read more →PRQRProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upc
Read more →PRQRProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in human Phase 1/2 clinical trial in adRP patients is expected to start in 2019 L
Read more →PRQRProQR Therapeutics N.V. Press Release
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved ther
Read more →PRQRProQR to Present at the Chardan Genetic Medicines Conference
LEIDEN, the Netherlands, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company will gi
Read more →PRQRProQR Announces Presentations at the OTS Annual Meeting
LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations
Read more →PRQRProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands &
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 6, 2018 ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines f
Read more →PRQRProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial QR-110 demonstrated rapid and sustained improvement in vision in the majori
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility c
Read more →PRQRProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th LEIDEN, The Netherlands and CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (
Read more →PRQRProQR Announces Financial Results for the Second Quarter of 2018
LEIDEN, The Netherlands, Aug. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced results
Read more →PRQRProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids
LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a pee
Read more →PRQRProQR Announces Presentations on Programs in Ophthalmology at Conferences in July
LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations a
Read more →PRQRProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a first-in-class potential therapeutic RNA molecule designed to improve the healing and
Read more →PRQRProQR to Present at the JMP Life Sciences Conference
LEIDEN, the Netherlands, June 14, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the company will gi
Read more →PRQRProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through
Read more →PRQRProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations a
Read more →PRQRProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr. Yi
Read more →PRQRPROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Financial Position
PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Financial Position March 31, 2018 December 31, 2017 1,000 1,000 Assets Current assets Cash and cash equivalents 38,001 48,099 Prepayments and other receivables 965 2,064 Social securit
Read more →PRQRProQR Announces Results for the First Quarter of 2018
Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with full data expected during 2019. ProQR and Galapagos N.V. entered into a research collaboration t
Read more →PRQRProQR Announces Conference Presentations for Axiomer RNA Editing Technology and QR-313 for DEB
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Company will p
Read more →PRQRProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled. The trial is on track to announce interim six-month data on safety, effects on vision and retinal structure in the second half of the year. ProQR to
Read more →PRQRProQR Announces Annual Meeting of Shareholders LEIDEN, the Netherlands
ProQR Announces Annual Meeting of Shareholders LEIDEN, the Netherlands, April 11, 2018 ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Le
Read more →PRQRProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer RNA A-to-I Editing Technology
Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I editing, Dr. Beal will be instrumental in advancing th
Read more →PRQRProQR to Present at Two Upcoming Conferences
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including Leber's congenital amaurosis 1
Read more →PRQRProQR to Present at Upcoming Investor Conference
LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's conge
Read more →PRQRProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Runway into the second half of 2019: cash of €48.0 million at year-end expected to fund operations through anticipated clinical data readouts in three different programs. First patient dosed in the Phase 1/2 safety & efficacy trial for QR-110 in children and adults with Leber’s
Read more →PRQRProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
LEIDEN, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congen
Read more →PRQRFoundation Fighting Blindness & ProQR Therapeutics N.V. Press Release
Foundation Fighting Blindness & ProQR Therapeutics N.V. Press Release February 12, 2018 Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR s candidate QR-421a for Usher syndrome type 2A COLUMBIA, MD, USA & LEIDEN, the Netherlands Fe
Read more →PRQRProQR to Present at Upcoming Scientific Meeting and Investor Conference
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congen
Read more →PRQRProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer technology
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). Under the agreement the two companies will work together to
Read more →PRQRProQR Announces Extraordinary General Meeting of Shareholders
LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16:00 CET, at the offices of the Company at Zernikedreef 9, 2333CK
Read more →PRQRProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA. QR-313 also received U.S. ODD from the FDA in September 2017. QR-313 represents the fifth candidate in the company’s pipeline to receive ODD in the
Read more →PRQRProQR to Present at the Annual Piper Jaffray Healthcare Conference
LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congeni
Read more →PRQRProQR Announces Results for the Third Quarter of 2017
Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that will fund operations through potential clinical data readouts in three different programs.
Read more →PRQRProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pr
Read more →PRQRProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital amaurosis 10 (LCA 10). LCA 10 is one of the most prevalent forms of gene-related blindness in childr
Read more →PRQRProQR Announces Proposed Public Offering of Ordinary Shares
LEIDEN, the Netherlands, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that i
Read more →PRQRProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
Dr. Thaddeus (Ted) Dryja, a pioneer in the field of retinal genetic diseases, joins the Company’s Scientific Advisory Board. Dr. Dryja will play a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The Netherlands, Nov. 09,
Read more →PRQRProQR to Present at EuroTIDES Conference
LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congen
Read more →PRQRProQR Announces Management Change and Key Promotions
Company announces departure of Noreen R. Henig, Chief Medical Officer, promotion of Peter Adamson to Senior Vice President Ophthalmology Franchise and Robert Friesen to Senior Vice President Science and Early Development. David M. Rodman, M.D., Chief Development Strategy Officer
Read more →PRQRProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congen
Read more →PRQRProQR to Present at the Chardan Inaugural Gene Therapy Conference
LEIDEN, the Netherlands, Oct. 06, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis, Leber's congen
Read more →PRQRProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment. A clinically meaningful improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a
Read more →PRQRProQR Presents in vivo Proof of Concept Data for the Axiomer RNA Editing Platform Technology
ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology. Axiomer® technology Editing Oligonucleotides (EONs) recruit endogenous ADAR to make single nucleotide changes to RNA in
Read more →PRQRProQR to Present at Two Investor Conferences in September
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of September. Cantor Fitzgerald Global Healthcare Conference On Tuesday, September 26, 20
Read more →PRQRProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive ODD in the U.S. The Company will be presenting pre-clinical data for QR-313 at two European
Read more →PRQRProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders and will be en
Read more →PRQRProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the fourth in the broader pipeline to receive ODD in the U.S. and EU. There are currently no ther
Read more →PRQRProQR Therapeutics N.V. Press Release September 5 , 2017 FINAL FOR RELEASE ProQR s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Key Updates ProQR s drug candidate QRX-421 fo
ProQR s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA LEIDEN, the Netherlands, September 5, 2017 ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that investigational drug QRX-421 for Usher syndrome has received orphan drug des
Read more →PRQRProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
Last patient received their final dose in the PQ-010-001 Phase 1b clinical trial of QR-010 in CF patients with the F508del mutation. Top-line trial data are expected to be issued in a press release post-market close on Monday, September 25, 2017, followed by a conference call.
Read more →PRQRProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases. The new members will join Dr. A
Read more →PRQRProQR Announces Results for the Second Quarter of 2017
Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference. Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September. The Investigational New Drug Application (IND) and
Read more →PRQRProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
ProQR’s QRX-411 receives Orphan Drug Designation by the FDA and EMA for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is an inherited condition that is characterized by combined deafness and blindness. QRX-411 ta
Read more →PRQRProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer , a novel proprietary RNA Technology
Key program features and updates: ProQR to host an R&D day in New York today, June 15, from 8:00am to 1:00pm Eastern Standard Time. The live webcast can be accessed at www.proqr.com/rd-day. Cystic Fibrosis (CF): Full data from the nasal potential difference (NPD) study for QR-0
Read more →PRQRProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Daniel de Boer, Chief Executive Officer, will participate in a panel discussion focused on emerging treatment options in cystic fibrosis during the JMP Securities
Read more →PRQRProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
An oral presentation on the final results from the proof-of-concept (PoC) nasal potential difference (NPD) trial will be given by Steve Rowe, MD at the European Cystic Fibrosis Society (ECFS) conference. Preliminary data from the Phase 1b study, PQ-010-001 single ascending dose
Read more →PRQRProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
ProQR receives Fast Track designation by the U.S. Food and Drug Administration (FDA). Closer interaction with FDA could potentially accelerate the development of QR-110 in patients with Leber’s Congenital Amaurosis Type 10 (LCA 10). LCA 10 is one of the most prevalent forms of g
Read more →PRQRProQR Announces Results for the First Quarter of 2017
QR-010 Phase 1b clinical trial on track to present top-line data in cystic fibrosis (CF) patients in mid-2017. Investigational new drug (IND) application for QR-110, ProQR’s lead program in ophthalmology, was cleared by the FDA to start a clinical trial in both adult and pediatr
Read more →PRQRProQR remembers co-founder Henri Termeer after his unexpected passing
LEIDEN, the Netherlands, May 15, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), remembers co-founder and supervisory board member Henri A. Termeer, who unexpectedly passed away Friday May 12, 2017 at age 71 at his house in Marblehead, MA. “We are devastated by t
Read more →PRQRProQR Announces R&D Day in New York on June 15
ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ET Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB) An update on the innovation
Read more →PRQRProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical trials for this program in both adult and pediatric patients. ProQR will also present data on it
Read more →PRQRProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10 (LCA 10) patients LCA 10 is one of the most prevalent forms of gene-rel
Read more →PRQRProQR to Present at the Deutsche Bank Health Care Conference
LEIDEN, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET. The co
Read more →PRQRProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033 QR-010 is currently being studied in 64 homozygous F508del patients in a Phase 1b safety, tolerability and exploratory efficacy trial. Top-line data to be reported
Read more →PRQRFINAL FOR RELEASE ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer LEIDEN, the Netherlands
ProQR Appoints David M. Rodman, MD as Development Strategy Officer LEIDEN, the Netherlands, March 27, 2017 ProQR Therapeutics N.V. (Nasdaq: PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in dr
Read more →PRQRProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in transl
Read more →PRQRProQR to Present at Two Upcoming Investor Conferences in March
LEIDEN, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's
Read more →PRQRProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
Major progress in the QR-010 development program for CF with presentation of positive clinical data at North American CF conference in October 2016 On track to report data from the ongoing Phase 1b trial of QR-010 in mid-2017 Finalizing preparations to start a Phase 1b/2 trial
Read more →PRQRProQR to Present at the LEERINK Partners Global Healthcare Conference
LEIDEN, the Netherlands, Feb. 07, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR Announces Results for the Third Quarter of 2016
LEIDEN, the Netherlands, Nov. 14, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR ANALYST & INVESTOR EVENT NACFC 2016, Orlando, Florida Date: Presenters: October 27th, 2016 Daniel de Boer, Noreen Henig and JP Clancy Agenda Overview and introduction by Daniel de Boer The relevance of the Nasal Po
ProQR ANALYST & INVESTOR EVENT NACFC 2016, Orlando, Florida Date: Presenters: October 27th, 2016 Daniel de Boer, Noreen Henig and JP Clancy Agenda Overview and introduction by Daniel de Boer The relevance of the Nasal Potential Difference test in CF by JP Clancy, M.D. Results
Read more →PRQRProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients
LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function in a cohort of homozygous
Read more →PRQRProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC
LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's conge
Read more →PRQRProQR to Present at Scientific and Investor Conferences in September
LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's conge
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position as of
PROQR THERAPEUTICS N.V. Condensed Consolidated Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position as of June 30, 2016 and December 31, 2015 1 Unaudited Condensed Consolidated Statement of Comprehensive Loss for the Three Month and S
Read more →PRQRProQR Announces Results for the Second Quarter of 2016
LEIDEN, the Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis
LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present pre-clinical data for QR-010 at the 39th European Cystic Fibrosis Conference (ECFS) held on June 8 – 11, 2016 in Basel, Switzerland and t
Read more →PRQRProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medici
Read more →PRQRProQR Announces Results for the First Quarter of 2016
LEIDEN, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congeni
Read more →PRQRProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting
LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present pre-clinical data for QR-110 which is being developed for Leber’s congenital amaurosis Type 10 (LCA10) at the 2016 Annual Meeting of the Ass
Read more →PRQRProQR to Highlight a Growing Pipeline During a Research & Development Day and Present at the Barclays Global Healthcare Conference
LEIDEN, the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's conge
Read more →PRQRProQR Announces Results for the Fourth Quarter and Full Year 2015
LEIDEN, the Netherlands, Feb. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic diseases including cystic fibrosis (CF) and Leber's con
Read more →PRQRProQR to Present at the Leerink Partners Global Healthcare Conference
LEIDEN, the Netherlands, Feb. 03, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR Announces R&D Day and Provides Update on Innovation Portfolio
LEIDEN, Netherlands, Nov. 30, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congenital
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Interim Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position as of
PROQR THERAPEUTICS N.V. Condensed Consolidated Interim Financial Statements PAGE Unaudited Condensed Consolidated Statement of Financial Position as of September 30, 2015 and December 31, 2014 1 Unaudited Condensed Consolidated Statement of Comprehensive Loss for the Thre
Read more →PRQRProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
LEIDEN, The Netherlands, Nov. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber's congen
Read more →PRQRProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences
LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present abstracts with pre-clinical data for its cystic fibrosis program at the 29th Annual North American Cystic Fibrosis Conference (NACFC) in Phoen
Read more →PRQRProQR to Present at the Leerink Partners 4th Annual Rare Disease Roundtable
LEIDEN, the Netherlands, Sept. 23, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amauro
Read more →PRQRProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment LEIDEN, the Netherlands
ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment LEIDEN, the Netherlands, September 14, 2015 ProQR Therapeutics N.V. (NASDAQ: PRQR) today announced that PQ-010-002 is open for enrollment. The primary objective of PQ-010-002
Read more →PRQRProQR Announces Results for the Second Quarter of 2015
LEIDEN, the Netherlands, Aug. 19, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis (CF) and Leber's congenital am
Read more →PRQRProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients LEIDEN, the Netherlands
ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients LEIDEN, the Netherlands, June 26, 2015 ProQR Therapeutics N.V. (NASDAQ: PRQR) today announced that enrollment has started in study PQ-010-001, a global Phase 1b clinical study
Read more →PRQRProQR to Present at the JMP Securities Life Science Conference
LEIDEN, the Netherlands, June 16, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amauros
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Interim Financial Statements PAGE Unaudited Condensed Statement of Financial Position as of
PROQR THERAPEUTICS N.V. Unaudited Condensed Interim Financial Statements PAGE Unaudited Condensed Statement of Financial Position as of March 31, 2015 and December 31, 2014 F-2 Unaudited Condensed Statement of Comprehensive Loss for the Three Month Period ended March 31,
Read more →PRQRProQR Therapeutics Announces Results for the First Quarter of 2015
LEIDEN, the Netherlands, May 21, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosi
Read more →PRQRProQR to Present at Two Upcoming Investor Conferences in May
LEIDEN, the Netherlands, April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), today announced that Daniel de Boer, Chief Executive Officer, will take part in a fireside chat at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at 2
Read more →PRQRProQR Therapeutics Announces Annual Shareholder Meeting LEIDEN, the Netherlands
ProQR Therapeutics Announces Annual Shareholder Meeting the Netherlands, April 29, 2015 ProQR Therapeutics N.V. (NASDAQ: PRQR), today announced that the Annual General Meeting of Shareholders will be held on Wednesday, June 10, 2015 at 16:00 CET, at Naturalis Biodiversity Center
Read more →PRQRProQR Therapeutics Announces Results for the Fourth Quarter and Full Year 2014
LEIDEN, Netherlands, Feb. 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis,
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Financial Statements PAGE Unaudited Condensed Statement of Financial Position as of
PROQR THERAPEUTICS N.V. Unaudited Condensed Financial Statements PAGE Unaudited Condensed Statement of Financial Position as of December 31, 2013 and December 31, 2014 F-2 Unaudited Condensed Statement of Comprehensive Loss for the Three Months Ended December 31, 2013 and
Read more →PRQRProQR to Present at the 2015 Leerink Global Healthcare Conference
LEIDEN, The Netherlands, Feb. 4, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, today announced that Daniel d
Read more →PRQRPROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Statement of Financial Position as of
Table of Contents Index to Unaudited Condensed Consolidated Financial Statements PAGE Unaudited Condensed Statement of Financial Position as of December 31, 2013 and September 30, 2014 F-2 Unaudited Condensed Statements of Comprehensive Loss for the Three Months Ended Sep
Read more →PRQRProQR Therapeutics Announces Results for the Third Quarter of 2014
LEIDEN, the Netherlands, Nov. 24, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, today announced results for
Read more →PRQRProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
LEIDEN, The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the und
Read more →PRQRProQR Announces Pricing of Initial Public Offering
LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share. In addition, ProQR has granted the underwriters a 3
Read more →Competitive Position
How PRQR ranks across every disease it competes inCompetitive Position is a premium feature
See how PRQR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial